AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02478112 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodegradable balloon implant
Description: Implantation under general anaesthesia of a biodegradable balloon before radiation therapy for prostate cancer
Study NCT02904369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Study NCT02904369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine
Study NCT02904369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide
Study NCT02904369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil
Study NCT03671252 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TME operation
Description: TME operation
Study NCT03671252 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: efficacy evaluation
Description: chest/ abdominal CT、pelvic nuclear magnetic resonanceimaging、transrectal ultrasonography
Study NCT03671252 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: efficacy evaluation
Description: chest/ abdominal CT、pelvic nuclear magnetic resonanceimaging、transrectal ultrasonography
Study NCT02376842 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Severe sepsis early warning best practice alert
Study NCT02376842 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Study NCT01657604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon α2b
Description: Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily with at a starting target dose of 30μg/week. After confirmed MMR or at least 24 mo. after start of therapy, maintenance therapy (nilotinib will be discontinued) will start for a study duration of up to 5 years.
Study NCT01657604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib
Description: Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily for a study duration of up to 5 years.
Study NCT00418613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK633
Description: MK0633 100mg capsules qd for a 12-wk treatment period.
Study NCT00418613 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo (unspecified)
Description: MK0633 100mg Pbo capsules for a 12-wk treatment period
Study NCT01227265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant
Description: Preladenant 2 mg or 5 mg oral tablet taken twice daily
Study NCT01227265 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Preladenant-matching placebo oral tablet taken twice daily
Study NCT01139944 — intervention group
Intervention type: GENETIC
Intervention: DNA methylation analysis
Study NCT01139944 — intervention group
Intervention type: GENETIC
Intervention: polymerase chain reaction
Study NCT01139944 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Study NCT04671615 — intervention group
Intervention type: DRUG
Intervention: palbociclib
Description: As provided in real world practice
Study NCT01718964 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cortisol 20 mg
Study NCT01718964 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mannitol
Description: Mannitol used as placebo
Study NCT01442701 — intervention group
Intervention type: OTHER
Intervention: Removal of triclosan-containing cleaning products from household.
Description: An intervention is nested within the observational cohort study as a secondary outcome. Commercially available household and personal cleaning products that either do not contain triclosan or that may contain triclosan will be delivered to the household every 4 months for the duration of the study. All cleaning products will be formulated, packaged and labeled by the original manufacturer with no modification for this study. Use of these products will be as per each individual product's label and at the discretion of the participant.
Study NCT02281344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV390048 20mg
Description: Supplied as a powder to be prepared as a suspension for oral use
Study NCT05134506 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance for PD® classes
Description: The intervention consisted of 16 60-min classes, performed twice weekly over a period of 8 weeks and instructed by a single researcher who had the approval to use it for research reasons.
Study NCT06406270 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fava
Description: Participants were instructed to consume only the meals that were provided to them during the study days. The breakfast, lunch and dinner meals of the diets were designed to contain 30% fat, 15% protein, and 55% carbohydrate, and seven different menus (1500, 1750, 2000, 2250, 2500, 2750 and 3000 Kcal) to deliver the closest energy requirements of the volunteers. For the intervention diets, all the meat was replaced with fava bean food products, serving the same amount of buckwheat and fava bean food products for all the volunteers independently of their energy requirements. During the intervention diets, all the drinks, such as coffee, juice and tea, were restricted and provided by the Human Nutrition Unit at the Rowett Institute; the volunteers were allowed to drink only water ad libitum. Alcoholic drinks were not allowed to be consumed during the intervention diet weeks.
Study NCT06406270 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buckwheat
Description: Participants were instructed to consume only the meals that were provided to them during the study days. The breakfast, lunch and dinner meals of the diets were designed to contain 30% fat, 15% protein, and 55% carbohydrate, and seven different menus (1500, 1750, 2000, 2250, 2500, 2750 and 3000 Kcal) to deliver the closest energy requirements of the volunteers. For the intervention diets, all the meat was replaced with buckwheat food products, serving the same amount of buckwheat and fava bean food products for all the volunteers independently of their energy requirements. During the intervention diets, all the drinks, such as coffee, juice and tea, were restricted and provided by the Human Nutrition Unit at the Rowett Institute; the volunteers were allowed to drink only water ad libitum. Alcoholic drinks were not allowed to be consumed during the intervention diet weeks.
Study NCT02637635 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous fat transplantation
Description: 100 ml of autologous fat will be injected to the reconstruction area 3 month prior the breast reconstruction with expander prosthesis.
Study NCT02637635 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Expander prosthesis
Description: breast reconstruction with expander prosthesis.
Study NCT02881138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC
Study NCT01339481 — intervention group
Intervention type: DRUG
Intervention: abatacept
Description: Intravenous Infusion
Study NCT00397163 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic preconditioning
Description: Blood pressure cuff inflation
Study NCT01462916 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: honey
Description: A crossover design (two 12-weeks intervention periods) will be used to measure treatment effects. The subjects will be randomized into two groups (intervention to control \[I/C\] and control to intervention \[C/I\] groups). Each study group will have 15 subjects. The subjects in the I/C group will consume 2 ml honey/kg/dose (maximum 50 ml/dose), twice weekly in the first 12-week period (period 1) while the subjects in the C/I group will not receive honey as a Control in period 1. After period 1 the subjects of each group will exchange their protocol for the following 12-week period (period 2).
Study NCT00972023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA
Description: DHEA administration will begin approxiately 14 days prior to surgery.
Study NCT04193670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical examination
Description: This is a classic dermatological clinical examination during a classic consultation
Study NCT00972023 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: Surgical procedure of the invasive breast cancer
Study NCT02332785 — intervention group
Intervention type: OTHER
Intervention: Data Collection
Description: Data collection of endoscopy procedure reports of participants with serrated polyps at MD Anderson Cancer Center in Houston, Texas.
Study NCT03183765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Measles-Mumps-Rubella Vaccine
Description: MMR vaccine will be injected 0.5 ml into the largest wart at 2-week intervals until complete clearance was achieved or for a maximum of 3 treatments.~Response to treatment will be evaluated 1 month after the last session by decrease in the size of warts, decrease in the number of warts and photographic comparison. The clinical response was graded into complete (complete cure), partial (if there was a decrease in the size and\\or a decrease in the total number of warts), and no response (no change in size and number of warts).
Study NCT03183765 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy
Description: patients received cryotherapy with liquid nitrogen once every 2 weeks until complete clearance or for a maximum of 3 sessions.Response to treatment will be evaluated 1 month after the last session by decrease in the size of warts, decrease in the number of warts and photographic comparison.~The clinical response was graded into complete (complete cure), partial (if there was a decrease in the size and\\or a decrease in the total number of warts), and no response (no change in size and number of warts).
Study NCT00002798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Study NCT00002798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Study NCT00002798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: daunorubicin hydrochloride
Study NCT00002798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Study NCT00002798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone
Study NCT00002798 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Study NCT00002798 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Study NCT00002798 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study NCT00002798 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: Given SC
Study NCT00002798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV or IT
Study NCT00002798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine
Description: Given IV or IT
Study NCT00002798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV
Study NCT04193670 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsies
Description: 2 skin biopsies on a lesion area selected according to the inclusion criteria (2 punchs of 4 mm) for each experimental group.~The first half of whole cutaneous biopsies (n = 25) will be studied using biphotonic microscopy. This will be performed on whole biopsies in 3-D according to the protocol developed in the laboratory.~The second half of whole skin biopsies (n = 25) will be studied using the technique of single-cell RNA seq.~The skin controls skin-free subjects will be obtained from skin reduction surgery (abdominoplasty) to subjects who have agreed to the use of their skin sample.
Study NCT04193670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood test
Description: A blood test on a tube (2 tubes of 10 mL).An assay of specific IgE and the serum level of IL-4, IL-13 and IL-5 will be carried out by ELISA (Enzyme Linked ImmunoSorbent Assay) from the blood samples.The blood samples will be obtained through the French blood establishment from different donors who have given their consent.
Study NCT04466072 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Stool test for microbial analysis
Description: Fecal samples will be analyzed by shotgun metagenomics and sample from the high ventricular arrhythmia burden will be compared with those from comparable control patients with low ventricular arrhythmia burden.
Study NCT04335708 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Postibiotic formulation
Description: 5 mL daily of edible gel with intracellular content of Lactobacillus casei CRL-431
Study NCT00002798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: idarubicin
Description: Given IV
Study NCT00002798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given PO
Study NCT00002798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Given PO
Study NCT00002798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: Given PO
Study NCT00002798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thioguanine
Description: Given PO
Study NCT04335708 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo formulation
Description: 5 mL daily of edible gel without intracellular content of Lactobacillus casei CRL-431
Study NCT03432611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-care information feature
Description: The self-care feature offers information on self-care for menstrual pain. The following topics are shown: exercise, dietary supplementation, heating pad/hot water bottle, yoga, and information on when to consult a doctor and how primary dysmenorrhoea is often treated. Notifications from the app which can be deactivated remind women of surveys and activities.
Study NCT03432611 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-care information feature
Description: The self-care feature offers information on self-care for menstrual pain. The following topics are shown: exercise, dietary supplementation, heating pad/hot water bottle, yoga, and information on when to consult a doctor and how primary dysmenorrhoea is often treated. Notifications from the app which can be deactivated remind women of surveys and activities.
Study NCT00002798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT03432611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-acupressure feature
Description: The acupressure feature offers detailed written and multimedia descriptions of an acupressure used for menstrual pain. Three acupressure points are described, which should be massaged bilaterally twice a day up to five times a day on the 5 days before menstruation and during menstruation. Each point should be massaged for 2 minutes. A timer for the acupressure and notifications from the app which can be deactivated remind women of surveys and acupressure.
Study NCT03432611 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-acupressure feature
Description: The acupressure feature offers detailed written and multimedia descriptions of an acupressure used for menstrual pain. Three acupressure points are described, which should be massaged bilaterally twice a day up to five times a day on the 5 days before menstruation and during menstruation. Each point should be massaged for 2 minutes. A timer for the acupressure and notifications from the app which can be deactivated remind women of surveys and acupressure.
Study NCT01340391 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omnicast
Description: dorsal splint 2-5 weeks
Study NCT02358564 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastrointestinal Permeability Test
Description: This test will involve ingesting a solution followed by urinalysis
Study NCT02358564 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastrointestinal Permeability Test
Description: This test will involve ingesting a solution followed by urinalysis
Study NCT02358564 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upper Endoscopy
Study NCT02358564 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper Endoscopy
Study NCT02358564 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectal Barostat and Infusion of Fats
Description: Feeding tube will be placed, as well as a small balloon in the rectum.
Study NCT02358564 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rectal Barostat and Infusion of Fats
Description: Feeding tube will be placed, as well as a small balloon in the rectum.
Study NCT01742533 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human umbilical cord mesenchymal stem cells
Study NCT01742533 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hUCMSCs and hCBMNCs
Study NCT01742533 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human cord blood mononuclear cells
Study NCT00397163 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Deflated cuff on upper arm and thigh for 20 min
Study NCT04298060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAS181
Description: SD (4.5mg/day), HD (9mg/day)
Study NCT04298060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 0mg/day
Study NCT03178565 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical insufflation-exsufflation
Description: The mechanical insufflation-exsufflation device will be connected in the orotracheal tube. Four series of insufflation-exsufflation will be conducted. Each serie will be composed by 10 cycles of alternated insufflation (40 cmH2O) and exsufflation (- 40 cmH2O).
Study NCT03178565 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Respiratory Physiotherapy
Description: Standard chest physiotherapy will be conducted through bilateral thoracic maneuvers (percussion and vibration) followed by manual hyperinflation using a manual resuscitator bag.
Study NCT02321735 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Quality of life questionaire
Description: Patients will participate in a QOL questionaire followed by a phone interview
Study NCT04570540 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sleep Study
Description: Full-night attended in-lab polysomnography with accompanying transcutaneous capnometry
Study NCT04570540 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary Function Test
Description: Bodyplethysmographic assessment
Study NCT04570540 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hypercapnic ventilatory response
Description: Measurement of hypercapnic ventilatory response based on the method described by Read in 1967, using a rebreathing bag
Study NCT04570540 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary Exercise Test
Description: Symptom-limited cardiopulmonary exercise test with a ramp protocol according to the ATS/ACCP and ERS recommendations
Study NCT01691924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-509
Study NCT01691924 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02774135 — intervention group
Intervention type: OTHER
Intervention: direct occupational therapy intervention
Description: Short term direct individual occupational therapy (9-12 weeks).Participants will receive occupational therapy intervention according to health law. The study will document the therapeutic intervention implemented in practice using the Documentation of Occupational Therapy Session during Intervention (DOTSI).
Study NCT02902536 — intervention group
Intervention type: OTHER
Intervention: No interventions
Study NCT00327288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imexon
Description: IV variable dosages, days 1-5 every 21 days for duration of study
Study NCT00327288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: IV once every 21 days for duration of study
Study NCT00325195 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo by intravenous infusion every 2 weeks
Study NCT00325195 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegloticase
Description: 8 mg pegloticase by intravenous infusion
Study NCT01584206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: 10mg ezetimibe/day, at least 4 months
Study NCT04927026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Where-there-is-no-psychiatrist Integrated Personal Therapy (WIPT)
Description: The WIPT include weekly face-to-face group sessions including mindfulness-based training and solution focused brief therapy (SFBT) involving psychoeducation and structured life review therapy catered to the personal needs of the participants.
Study NCT03450395 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hot Cereal
Description: Intervention involves consumption of one hot cereal in the beginning of each day
Study NCT03450395 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot Cereal
Description: Intervention involves consumption of one hot cereal in the beginning of each day
Study NCT04319159 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: BF-200 ALA and red light LED lamp
Description: Combination Product: Photodynamic therapy (PDT) using BF-RhodoLED® (ALA-PDT, Ameluz®-PDT).